Robert P. Law

Robert P. Law

Auto-generated profile, based on publicly available information

Robert P. Law

Medicinal Chemistry GSK Medicines Research Centre Gunnels Wood Road SG1 2NY Stevenage Hertfordshire United Kingdom

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
RLRobert P. Law
Robert P. Law
JNJoao Nunes
Joao Nunes
CCChun‐Wa Chung
Chun‐Wa Chung
MBMarcus Bantscheff
Marcus Bantscheff
KBKarol Buda
Karol Buda
ABAndrew B. Benowitz
Andrew B. Benowitz

15 April 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RLRobert P. Law
Robert P. Law
SAStephen J. Atkinson
Stephen J. Atkinson
PBPaul Bamborough
Paul Bamborough
CCChun-Wa Chung
Chun-Wa Chung
EDEmmanuel H. Demont
Emmanuel H. Demont
DHDavid Jonathan Hirst
David Jonathan Hirst

7 November 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRebecca Stevens
Rebecca Stevens
EBEnrique Bendito-Moll
Enrique Bendito-Moll
DBDavid J. Battersby
David J. Battersby
AMAfjal H. Miah
Afjal H. Miah
NWNatalie Wellaway
Natalie Wellaway
JHJohn D. Harling
John D. Harling

1 August 2021 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
PSPeter Stacey
Peter Stacey
HLHannah Lithgow
Hannah Lithgow
XLXiao Lewell
Xiao Lewell
AKAgnieszka Konopacka
Agnieszka Konopacka
SBStephen Besley
Stephen Besley
MMMarcel Muelbaier
Marcel Muelbaier
Targeted protein degradation is an emerging new strategy for the modulation of intracellular protein levels with applications in chemical biology and drug discovery. One approach to enable this strategy is to redirect the ubiquitin–proteasome system to mark and degrade target proteins of interest (POIs) through the use of proteolysis targeting chimeras (PROTACs). Although great progress has been made in enabling PROTACs as a platform, there are still a limited number of E3 ligases that have been employed for PROTAC design. Herein we report a novel phenotypic screening approach for the identification of E3 ligase binders. The key concept underlying this approach is the high-throughput modification of screening compounds with a chloroalkane moiety to generate HaloPROTACs in situ, which were then evaluated for their ability to degrade a GFP-HaloTag fusion protein in a cellular context. As proof of concept, we demonstrated that we could generate and detect functional HaloPROTACs in situ, using a validated Von Hippel–Lindau (VHL) binder that successfully degraded the GFP-HaloTag fusion protein in living cells. We then used this method to prepare and screen a library of approximately 2000 prospective E3 ligase-recruiting molecules.

6 November 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
RHRoss P. Hryczanek
Ross P. Hryczanek
AHAndrew S. Hackett
Andrew S. Hackett
PRPaul Rowland
Paul Rowland
CCChun-Wa Chung
Chun-Wa Chung
MCMáire A. Convery
Máire A. Convery
Efstratios StratikosEfstratios Stratikos
Efstratios Stratikos
Endoplasmic reticulum aminopeptidase 1 (ERAP1) cleaves the N-terminal amino acids of peptides, which can then bind onto major histocompatibility class I (MHC-I) molecules for presentation onto the cell surface, driving the activation of adaptive immune responses. In cancer, overtrimming of mature antigenic peptides can reduce cytotoxic T-cell responses, and ERAP1 can generate self-antigenic peptides which contribute to autoimmune cellular responses. Therefore, modulation of ERAP1 activity has potential therapeutic indications for cancer immunotherapy and in autoimmune disease. Herein we describe the hit-to-lead optimization of a series of cyclohexyl acid ERAP1 inhibitors, found by X-ray crystallography to bind at an allosteric regulatory site. Structure-based drug design enabled a >1,000-fold increase in ERAP1 enzymatic and cellular activity, resulting in potent and selective tool molecules. For lead compound 7, rat pharmacokinetic properties showed moderate unbound clearance and oral bioavailability, thus highlighting the promise of the series for further optimization.

20 August 2021 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
RLRobert P. Law
Robert P. Law
JNJoao Nunes
Joao Nunes
CCChun‐Wa Chung
Chun‐Wa Chung
MBMarcus Bantscheff
Marcus Bantscheff
KBKarol Buda
Karol Buda
ABAndrew B. Benowitz
Andrew B. Benowitz